dipyridamole has been researched along with Neoplasms in 37 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Eighty-eight patients with advanced cancer were entered into this Phase I trial." | 2.68 | Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. ( Capizzi, RL; Case, L; Fernandes, DJ; Fleming, RA; Homesley, H; Loggie, BW; Morris, R; Muss, HB; Richards, F; Russell, GB; Smith, S, 1996) |
| "Stomatitis was observed in 44/78 (56%) courses." | 2.67 | A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Grem, JL; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1992) |
| "Dipyridamole was introduced on the market as coronary vasodilator drug more than half a century ago and is still used as antithrombotic and vasodilator." | 2.52 | Dipyridamole: a drug with unrecognized antioxidant activity. ( Ciacciarelli, M; Iuliano, L; Violi, F; Zerbinati, C, 2015) |
| "Dipyridamole, which acts as an anti-thrombotic agent by modulating multiple targets and has a long history of safe use, was identified to interact with HSP90's N-terminal domain." | 1.91 | Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines. ( Gao, J; Li, M; Luo, X; Shi, L; Su, H; Xu, Y; Zhang, N; Zhong, Y; Zhou, C; Zhou, H, 2023) |
| "Among ovarian cancer cell lines tested, the enhancement of the activity of HuIFN by dipyridamole for HAC-2 and SHIN-3 cells was equivalent to or greater than that for 3 chemotherapy agents (adriamycin, vincristine, and a camptothecin derivative)." | 1.28 | Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells. ( Fukazawa, I; Inaba, N; Isogai, E; Oiwa, Y; Saito-Ebihara, M; Sekiya, S; Sugano, I; Suzuki, N; Takakubo, Y; Yoshida, J, 1992) |
| "Gabexate Mesilate was thought to be effective and free from complication in case 4, 5." | 1.28 | [Report of five cases of major surgery during anticoagulant therapy after prosthetic valve replacement]. ( Abe, T; Hagiwara, K; Hoshino, S; Igari, T; Iwatani, F; Midorikawa, H; Sadogawa, H; Sato, Y; Tanji, M; Watanabe, M, 1990) |
| "Dipyridamole was administered in a fixed dose of 7." | 1.28 | Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. ( Alberti, DB; Bruggink, J; Fischer, PH; Grem, JL; Nieting, LM; Remick, SC; Tombes, MB; Trump, DL; Tutsch, KD; Willson, JK, 1990) |
| "Dipyridamole did not increase toxicity by an alteration in methotrexate elimination." | 1.28 | Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. ( Alberti, D; Bruggink, J; Fischer, PH; Grem, JL; Nieting, L; Remick, SC; Trump, DL; Tutsch, KD; Willson, JK, 1989) |
| " The peritoneal decay data for dipyridamole fitted very well to a single compartment open pharmacokinetic model with one exponential term, while the plasma data are adequately described by a single compartment model with two exponentials (a short absorption phase)." | 1.27 | Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ( Chan, TC; Cleary, S; Coppoc, GL; Howell, SB; Zimm, S, 1988) |
| "Fischer et al." | 1.27 | Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. ( Alberti, D; Bruggink, J; Earhart, RH; Fischer, PH; Hamilton, RD; Koeller, JM; Simon, K; Tormey, DC; Tutsch, K; Willson, JK, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (45.95) | 18.7374 |
| 1990's | 9 (24.32) | 18.2507 |
| 2000's | 5 (13.51) | 29.6817 |
| 2010's | 3 (8.11) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Gao, J | 2 |
| Zhou, C | 2 |
| Zhong, Y | 2 |
| Shi, L | 2 |
| Luo, X | 2 |
| Su, H | 2 |
| Li, M | 2 |
| Xu, Y | 2 |
| Zhang, N | 2 |
| Zhou, H | 2 |
| Longo, J | 1 |
| Pandyra, AA | 1 |
| Stachura, P | 1 |
| Minden, MD | 1 |
| Schimmer, AD | 1 |
| Penn, LZ | 1 |
| Urbina, F | 1 |
| Puhl, AC | 1 |
| Ekins, S | 1 |
| Ciacciarelli, M | 1 |
| Zerbinati, C | 1 |
| Violi, F | 1 |
| Iuliano, L | 1 |
| Nosengo, N | 1 |
| de Anta, JM | 1 |
| Mayo, C | 1 |
| Solé, F | 1 |
| Salido, M | 1 |
| Espinet, B | 1 |
| Corzo, C | 1 |
| Petzold, M | 1 |
| Villa, O | 1 |
| Serrano, S | 1 |
| Real, FX | 1 |
| Mayol, X | 1 |
| Goda, AE | 1 |
| Yoshida, T | 1 |
| Horinaka, M | 1 |
| Yasuda, T | 1 |
| Shiraishi, T | 1 |
| Wakada, M | 1 |
| Sakai, T | 1 |
| Phillis, JW | 1 |
| Wu, PH | 1 |
| Turpie, AG | 1 |
| Bates, SE | 1 |
| Regis, JI | 1 |
| Robey, RW | 1 |
| Zhan, Z | 1 |
| Scala, S | 1 |
| Meadows, BJ | 1 |
| Jansen, WJ | 1 |
| Pinedo, HM | 1 |
| van der Wilt, CL | 1 |
| Feller, N | 1 |
| Bamberger, U | 1 |
| Boven, E | 1 |
| Stewart, DJ | 2 |
| Cripps, MC | 1 |
| Goel, R | 1 |
| Dahrouge, S | 1 |
| Yau, J | 1 |
| Tomiak, E | 1 |
| Huan, S | 1 |
| Soltys, K | 1 |
| Prosser, A | 1 |
| Davies, RA | 1 |
| Fleming, RA | 1 |
| Capizzi, RL | 1 |
| Muss, HB | 1 |
| Smith, S | 1 |
| Fernandes, DJ | 1 |
| Homesley, H | 1 |
| Loggie, BW | 1 |
| Case, L | 1 |
| Morris, R | 1 |
| Russell, GB | 1 |
| Richards, F | 1 |
| Krishan, A | 1 |
| Sridhar, KS | 1 |
| Mou, C | 1 |
| Stein, WD | 1 |
| Lyubimov, E | 1 |
| Hu, YP | 1 |
| Fernandez, H | 1 |
| Raschko, JW | 1 |
| Synold, TW | 1 |
| Chow, W | 1 |
| Coluzzi, P | 1 |
| Hamasaki, V | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Shibata, SI | 1 |
| Somlo, G | 1 |
| Tetef, ML | 1 |
| Yen, Y | 1 |
| ter Veer, A | 1 |
| Doroshow, JH | 1 |
| Dollinger, MR | 1 |
| Krakoff, IH | 1 |
| Suzuki, N | 1 |
| Oiwa, Y | 1 |
| Sugano, I | 1 |
| Inaba, N | 1 |
| Sekiya, S | 1 |
| Fukazawa, I | 1 |
| Yoshida, J | 1 |
| Takakubo, Y | 1 |
| Isogai, E | 1 |
| Saito-Ebihara, M | 1 |
| Bailey, H | 1 |
| Wilding, G | 1 |
| Tutsch, KD | 3 |
| Arzoomanian, RZ | 1 |
| Alberti, D | 3 |
| Tombes, MB | 2 |
| Grem, JL | 4 |
| Spriggs, DR | 1 |
| Midorikawa, H | 1 |
| Iwatani, F | 1 |
| Igari, T | 1 |
| Abe, T | 1 |
| Hagiwara, K | 1 |
| Tanji, M | 1 |
| Sadogawa, H | 1 |
| Watanabe, M | 1 |
| Sato, Y | 1 |
| Hoshino, S | 1 |
| Mareel, M | 1 |
| Bracke, M | 1 |
| Bruyneel, E | 1 |
| Van Larebeke, N | 1 |
| De Mets, M | 2 |
| Remick, SC | 2 |
| Fischer, PH | 4 |
| Alberti, DB | 1 |
| Nieting, LM | 1 |
| Bruggink, J | 3 |
| Willson, JK | 3 |
| Trump, DL | 2 |
| Higano, CS | 1 |
| Livingston, RB | 1 |
| Evans, WK | 1 |
| Mareel, MM | 1 |
| Nieting, L | 1 |
| Bastida, E | 1 |
| del Prado, J | 1 |
| Almirall, L | 1 |
| Jamieson, GA | 1 |
| Ordinas, A | 1 |
| Chan, TC | 3 |
| Coppoc, GL | 1 |
| Zimm, S | 1 |
| Cleary, S | 3 |
| Howell, SB | 3 |
| Tutsch, K | 1 |
| Simon, K | 1 |
| Hamilton, RD | 1 |
| Koeller, JM | 1 |
| Tormey, DC | 1 |
| Earhart, RH | 1 |
| Markman, M | 2 |
| Gastpar, H | 1 |
| Abrahamsen, AF | 1 |
| Harker, LA | 1 |
| Slichter, SJ | 1 |
| Dacie, JV | 1 |
11 reviews available for dipyridamole and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Recent advances in drug repurposing using machine learning.
Topics: Alzheimer Disease; Antineoplastic Agents; Antiviral Agents; Clemastine; Computational Biology; COVID | 2021 |
Dipyridamole: a drug with unrecognized antioxidant activity.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Central Nervous System Diseases; Dipyridamole; Drug | 2015 |
Adenosine may regulate the vascular supply and thus the growth and spread of neoplastic tissues: a proposal.
Topics: Adenosine; Animals; Dipyridamole; Humans; Neoplasm Metastasis; Neoplasms | 1981 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Chemoresistance in the clinic: overview 1994.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dipyridamole; Drug Resistance | 1994 |
Invasion and metastasis control: implications for increased therapeutic index of antitumor drugs.
Topics: Antineoplastic Agents; Catechin; Dipyridamole; Glycoproteins; Humans; Microtubules; Neoplasm Invasiv | 1990 |
Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.
Topics: Animals; Biological Transport; Cell Line, Transformed; Dipyridamole; Drug Screening Assays, Antitumo | 1989 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chem | 1989 |
Anti-invasive activities of experimental chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Catechin; Dipyridamole; Flavones; Flavonoids; Glucosidases; Glycosyl | 1989 |
[The inhibition of cancer cell stickiness by pyrimido-pyrimidine derivatives].
Topics: Animals; Cell Adhesion; Dipyridamole; Dose-Response Relationship, Drug; Mesentery; Molecular Conform | 1973 |
8 trials available for dipyridamole and Neoplasms
| Article | Year |
|---|---|
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Chemoresistance in the clinic: overview 1994.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dipyridamole; Drug Resistance | 1994 |
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoylt | 1996 |
Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Survival; Colonic Neoplasms; Culture Media; D | 2000 |
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2000 |
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi | 1992 |
Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dipy | 1989 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chem | 1989 |
21 other studies available for dipyridamole and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Dipyridamole; HSP90 Heat-S | 2023 |
Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Dipyridamole; HSP90 Heat-S | 2023 |
Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Dipyridamole; HSP90 Heat-S | 2023 |
Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Dipyridamole; HSP90 Heat-S | 2023 |
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Topics: Cell Death; Cell Line, Tumor; Cilostazol; Cyclic AMP; Dipyridamole; Drug Synergism; Humans; Hydrolys | 2020 |
Can you teach old drugs new tricks?
Topics: Animals; Azoles; Bipolar Disorder; Carbazoles; Clinical Trials, Phase II as Topic; Dipyridamole; Dru | 2016 |
Methotrexate resistance in vitro is achieved by a dynamic selectionprocess of tumor cell variants emerging during treatment.
Topics: Cell Line, Tumor; Cell Proliferation; Chromosomal Instability; Dipyridamole; Drug Resistance, Neopla | 2006 |
Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
Topics: Apoptosis; Blotting, Northern; Bone Neoplasms; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinas | 2008 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; | 1995 |
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antifungal | 1997 |
Hemolysis induced by 6-N-hydroxylaminopurine riboside, an adenosine analogue.
Topics: Adenosine; Adult; Bilirubin; Blood Cell Count; Breast Neoplasms; Dipyridamole; Erythrocytes; Female; | 1975 |
Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Div | 1992 |
[Report of five cases of major surgery during anticoagulant therapy after prosthetic valve replacement].
Topics: Adult; Anticoagulants; Dipyridamole; Female; Gabexate; Guanidines; Heart Valve Prosthesis; Heparin; | 1990 |
Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Drug Administration Sched | 1990 |
Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Humans; Methotrexate; Neoplasms; Nucle | 1989 |
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Topics: Cell Division; Cell Line; Coagulants; Cyclic AMP; Dipyridamole; Humans; Neoplasms; Nucleosides; Plat | 1985 |
Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients.
Topics: Aged; Blood Proteins; Dipyridamole; Female; Humans; Infusions, Parenteral; Metabolic Clearance Rate; | 1988 |
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Dipyridamole; | 1988 |
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyridamole; Drug Evaluation; Female | 1986 |
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyr | 1987 |
The effect of acetylsalicylic acid and dipyridamole on platelet economy in metastatic cancer.
Topics: Aspirin; Blood Cell Count; Blood Platelets; Cell Survival; Dipyridamole; Half-Life; Humans; Neoplasm | 1972 |
Platelet and fibrinogen consumption in man.
Topics: Blood Cell Count; Blood Platelets; Catheterization; Cell Survival; Dipyridamole; Disseminated Intrav | 1972 |
[Hemolytic-uremic syndrome and microangiopathic hemolytic anemia].
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic; Aspirin; Dextrans; Dipyridamole; Drug Hypersensitivity; | 1973 |